StemCyte Introduces Innovative Cord Blood Insurance Model in Taiwan to Enhance Cell Therapy Access
StemCyte Launches Insurance-Linked Cord Blood Access in Taiwan
In a groundbreaking initiative, StemCyte International has unveiled the first public cord blood banking system in Taiwan that integrates insurance coverage. This innovative program, known as the Public Bank Matching Protection Service, is a collaborative effort with Taishin Life, a prominent insurance company. It aims to enhance accessibility for families seeking to utilize cord blood for cell therapy purposes, showcasing StemCyte's commitment to pioneering solutions in regenerative medicine.
A New Era in Cord Blood Banking
StemCyte’s announcement marks a historic moment in the realm of cord blood banking, as it is the only organization in Taiwan to segment insurance with public cord blood resources. The integration of insurance into this service allows families to not only store cord blood but also have it insured, mitigating potential financial risks associated with medical treatments. This model is expected to redefine the standard of healthcare offerings in the region, specifically in how families engage with critical health resources.
At the heart of this new offering is the REGENECYTE® (HPC, Cord Blood), a product that received U.S. FDA Biologics License Application approval in late 2024, making StemCyte the sole private cord blood entity with FDA-approved therapy for unrelated allogeneic transplants. This achievement reflects over two decades of scientific and clinical excellence that is now being harnessed to save lives and enhance patient outcomes across various health complications.
Enhancing Patient Access to Cell Therapy
Dr. Tong-Young Lee, CEO of StemCyte, emphasized the fundamental value of integrating insurance coverage with cord blood access. He stated, “The true value of cord blood protection lies in its ability to save lives in critical moments... We are the first to integrate this innovative service with the insurance system, enabling more people to receive immediate support for cell therapy.” This statement underscores the commitment StemCyte has towards ensuring that those in critical need of cell therapy are not limited by financial constraints.
The initiative is underpinned by an impressive track record of over 2,300 successful transplants executed by StemCyte, quantifiably marking it as one of the leading entities in the sphere of cord blood banking. Moreover, the company adheres to strict quality standards, validated by various accreditations including FACT and AABB and participation in the NMDP Network, along with TFDA GMP/GTP certifications.
A Foundation for Future Partnerships
This pioneering service in Taiwan is just the beginning. StemCyte has plans to forge further partnerships in the United States and expand services to the ASEAN region and beyond. With the aid of artificial intelligence for HLA matching, the company looks to decrease the time required for matches, while simultaneously investing in smart manufacturing technologies to enhance their international distribution capabilities.
StemCyte's efforts are being recognized globally; in 2025, the company was honored with the Taiwan BIO Award for Innovation of the Year and received accolades from President Lai Ching-te at the Presidential Office. These achievements not only underscore their leadership in cell therapy but also their ongoing efforts to innovate and expand the accessibility of lifesaving treatments worldwide.
About StemCyte
Founded in 1997, StemCyte operates globally with facilities in the United States, Taiwan, and India. The company has been a pivotal player in the cord blood banking industry, having facilitated more than 2,300 transplants and maintaining a robust public inventory of over 36,000 donated units. As the only private cord blood bank with an FDA-approved BLA for unrelated allogeneic use, StemCyte is committed to expanding access to clinically proven therapies through its accredited dual public-private model.
To learn more about StemCyte’s innovative services and their impact on regenerative medicine, visit www.stemcyte.com.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.